Icagen institutional investors call Pfizer's $56M offer inadequate

08/14/2011 | MedCityNews.com

Merlin Nexus and New Leaf Venture Partners, Icagen's institutional investors, reiterated their opposition to Pfizer's $56 million offer for the drugmaker, saying the bid is inadequate. Icagen, which is developing painkillers, should be priced $11 to $19 a share, or $100 million to $165 million, the investors said in a letter to Icagen's board of directors.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Claims Director
Springfield, OR
Director of ASO Department
Bluegrass Family Health
Lexington-or could be in Nashville, TN, KY
Attest Health Care Advisors
Nationwide, SL_Nationwide
Mgr NGS Provider Enrollment (I)
National Government Services - WellPoint
Harrisburg, PA
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA